Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Araclon Biotech S.L.
DescriptionActive immunotherapy targeting the C-terminal fragment of beta amyloid 40
Molecular Target Beta amyloid 40
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat mild to moderate Alzheimer's disease (AD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today